However, recent guidelines have prioritized the use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) for managing diabetes during Ramadan fasting considering their benefits including weight management, cardiovascular benefits, renal protection, and flexibility in dosing, though caution is advised regarding potential hypoglycemia when combined with insulin or sulphonylureas (20, 21). The gene discussed is INS; the disease is Hypoglycemia.